Veracyte, Inc.
VCYT
$30.43
-$0.53-1.71%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 118.63M | 115.86M | 114.43M | 96.84M | 98.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 118.63M | 115.86M | 114.43M | 96.84M | 98.20M |
| Cost of Revenue | 37.07M | 33.93M | 33.61M | 47.43M | 29.38M |
| Gross Profit | 81.57M | 81.93M | 80.82M | 49.42M | 68.82M |
| SG&A Expenses | 50.81M | 48.35M | 55.16M | 43.79M | 48.94M |
| Depreciation & Amortization | 3.61M | 3.80M | 3.79M | 3.65M | 4.56M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.78M | 103.66M | 109.02M | 94.87M | 101.55M |
| Operating Income | 7.85M | 12.20M | 5.41M | 1.98M | -3.35M |
| Income Before Tax | 3.44M | 16.85M | 7.36M | -1.91M | -30.47M |
| Income Tax Expenses | -1.67M | 1.69M | 1.63M | -44.00K | -2.18M |
| Earnings from Continuing Operations | 5.11M | 15.16M | 5.73M | -1.86M | -28.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.11M | 15.16M | 5.73M | -1.86M | -28.29M |
| EBIT | 7.85M | 12.20M | 5.41M | 1.98M | -3.35M |
| EBITDA | 14.11M | 18.08M | 11.14M | 7.57M | 2.99M |
| EPS Basic | 0.07 | 0.20 | 0.07 | -0.02 | -0.39 |
| Normalized Basic EPS | 0.06 | 0.14 | 0.07 | 0.04 | 0.01 |
| EPS Diluted | 0.06 | 0.19 | 0.07 | -0.02 | -0.39 |
| Normalized Diluted EPS | 0.06 | 0.14 | 0.07 | 0.04 | 0.01 |
| Average Basic Shares Outstanding | 77.61M | 77.01M | 76.54M | 74.76M | 73.11M |
| Average Diluted Shares Outstanding | 79.91M | 78.46M | 77.16M | 74.76M | 73.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
